# AltruBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/altrubio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.altrubio.com
- Total disclosed funding: $288M
- Latest round: Series B (May 21, 2024)
- Investors on record: 8

## About

Established in 2020 and based in California, US, AltruBio, Inc., formerly known as AbGenomics Holding Inc. operates as a clinical-stage biotechnology that focuses on the discovery and development of targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. It has a R&D centre in Taipei.  The chairman and CEO of the company, Judy Chou graduated from Yale University and has worked in Bayer AG, Pfizer, and Medivation. In May 2024, the company raised USD 225 million in series B funding led by returning investor BVF Partners. The company mainly provides anti-immune inflammation drug ALTB-168, which is a humanized therapeutic target antibody. ALTB-168 can be used to treat diseases such as psoriasis, psoriatic arthritis, ulcerative colitis, and GVHD (Graft-versus-host disease). AltruBio also provides immunity drug candidates ALTB-268, which can be used to treat ulcerative colitis and psoriatic arthritis. The company plans to use the funding to advance the clinical development of its novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody ALTB-268 and to support ongoing and planned Phase 2 clinical trials in ulcerative colitis.

## Funding rounds

- Series B, May 21, 2024, $225M — Blackstone Group, BVF Partners, RA Capital Management, Delos Capital, Cormorant Asset Management, aMoon, Soleus Capital
- Series A, Apr 15, 2021, $63M — CAM Capital, BVF Partners, aMoon

## Investors

- CAM Capital — Series A
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A, Series B
- aMoon (https://capitalatlas.ai/funds/amoon) — Series A, Series B
- Blackstone Group (https://capitalatlas.ai/funds/blackstone-group) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Delos Capital (https://capitalatlas.ai/funds/delos-capital) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series B